- Home
- REFI vs SLP Comparison
REFI vs SLP Comparison
Compare REFI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | SLP |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | EDP Services |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 250.6M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | REFI | SLP |
|---|---|---|
| Price | $12.30 | $11.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $20.00 | ★ $25.00 |
| AVG Volume (30 Days) | 123.8K | ★ 195.4K |
| Earning Date | 03-12-2026 | 04-02-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.68 | 0.03 |
| Revenue | $48,857,628.00 | ★ $59,577,000.00 |
| Revenue This Year | $19.62 | $2.64 |
| Revenue Next Year | $10.79 | $6.01 |
| P/E Ratio | ★ $7.42 | $390.50 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $11.62 | $11.16 |
| 52 Week High | $15.49 | $36.43 |
Technical Indicators
Market Signals| Indicator | REFI | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 32.33 |
| Support Level | $12.23 | $11.16 |
| Resistance Level | $12.46 | $12.70 |
| Average True Range (ATR) | 0.25 | 0.48 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 54.83 | 14.62 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.